Donald A. Holzworth
Chairman, Futures Group International
Donald A. Holzworth was the former Founder, Chairman, and Chief Executive Officer of Constella Group, a leading global provider of health consulting services dedicated to enhancing human health around the world, every day. In August 2007, Holzworth completed the sale of Constella to SRA International, Inc., a $1.5 billion technology services and consulting firm, for $185 million. In September of 2008, Holzworth repurchased Futures Group, International, a former division of Constella Group, and now serves as the Company’s Chairman.
From 1991 to 2007, Holzworth guided Constella’s revenue growth to more than $200 million, increased the company’s number of employees to more than 1,500, and the scope of the company’s operations to 61 countries. In 2003 and again in 2007, the North Carolina Council for Entrepreneurial Development recognized Constella with its Entrepreneurial Excellence Award. In 2005, Ernst & Young named Holzworth as a Carolinas Entrepreneur of the Year® and he now serves as both a regional and national judge for this prestigious program.
Prior to Constella, Mr. Holzworth spent 9 years as a senior executive with another consulting firm, leading that company’s life sciences business and growth from $6 million to $70 million in revenue before its sale in 1990. In 2002, Holzworth was a co-founder and served as the inaugural CEO of Expression Analysis, Inc., a start-up genomic services company spun out of Duke University Medical Center. He now serves as the company’s Chairman of the Board. He also serves as Chairman of Casey Petraceuticals, a pet nutrition products company and on the Board of the Campbell Alliance Group, a management consulting firm serving the pharmaceutical and biotech industries, and on the Advisory Board for Southern Capitol Ventures.
His public health experience has led to an appointment to the Presidential Advisory Council on HIV/AIDS and to the Board of the Accordia Global Health Foundation. He is an Executive in Residence at the UNC Gillings School of Global Public Health, a member of the School’s Advisory Council, Acceleration Advisory Committee, and Adjunct Professor of Health Policy and Management.
Michael W. Marine
Board Member
Michael W. Marine culminated his 32-year career in the U.S. State Department’s Foreign Service by serving as U.S. Ambassador to the Socialist Republic of Vietnam from September 2004 to August 2007.
Mr. Marine was Deputy Chief of Mission (DCM) at the U.S. Embassy in Beijing, China from September 2000 to June 2004. He was DCM in Nairobi, Kenya from August 1997 to June 2000. In the wake of the devastating August 1998 terrorist attack on Embassy Nairobi, he served as Charge d’Affaires (CDA) there from May 1999 until September 1999. He was Minister Counselor for Consular Affairs (MCCA) at Embassy Moscow 1995-1997 and MCCA at Embassy Bonn 1994-1995. From 1991 to January 1993, he was DCM at Embassy Suva, Fiji. From February 1993 until April 1994, he served as CDA at Embassy Suva. From 1985 to 1991, Mr. Marine served in a series of jobs at the Department of State in Washington, DC, including three years as Special Assistant to the Assistant Secretary for Consular Affairs (CA) and one year as Director of CA’s Office of Fraud Prevention Programs.
Born in New York City in 1947, Mr. Marine enlisted in the U.S. Marine Corps in 1967 and completed his service with the rank of Captain in 1971. He received a BA in Asian Studies, summa cum laude, from the University of California at Santa Barbara in 1974 and entered the Foreign Service in 1975. His early assignments were as a consular officer in Martinique, London, and Guangzhou, China, and as a political officer in Hong Kong. He received the State Department’s Superior Honor Award six times.
Ambassador Mark R. Dybul
Board Member
Ambassador Mark R. Dybul co-directs the Global Health Law Program at Georgetown University Law Center’s O’Neill Institute for National and Global Health Law, where he is also a Distinguished Visiting Scholar. He is the inaugural Global Health Fellow of the George W. Bush Institute and serves as the Managing Director of the Office of the United Nation Special Envoy for Malaria. Ambassador Dybul served as the United States Global AIDS Coordinator from 2006 to the end of the George W. Bush administration. In that role, he led the implementation of the President’s Emergency Plan for AIDS Relief (PEPFAR), the largest international health initiative in history for a single disease. Ambassador Dybul oversaw the United States government engagement in the Global Fund to Fight AIDS, Tuberculosis and Malaria and was the Chair of the Finance and Audit Committee. He also served as chair of the Joint United Nations Programme on HIV/AIDS’ coordinating board and as a member of the board of trustees of the Woodrow Wilson International Center for Scholars. Prior to assuming the post of Ambassador, he was Acting, Deputy and Assistant Coordinator, and was a member of the Planning Task Force that created PEPFAR. He also led President Bush’s International Prevention of Mother and Child HIV initiative at the Department of Health and Human Services (HHS), was the Executive Secretary for HHS guideline for adult and adolescent HIV therapy and was a member of the writing committee for the World Health Organization’s guidelines on the use of antiretroviral therapy. At HHS, Ambassador Dybul served as the Assistant Director for Medical Affairs at the National Institute of Allergy and Infectious Diseases and the National Institutes of Health, and was the principal investigator of basic and clinical research with a particular emphasis on HIV treatment in Africa. He is well published in scientific and policy literature, has received several honorary degrees and significant awards, and has served on numerous national and international boards.
Ambassador Dybul received his A.B. in philosophy and M.D. from Georgetown University before completing a residency in Internal Medicine at the University of Chicago Medical Center in 1992 and a fellowship in Infectious Diseases from the National Institute of Allergy and Infectious Diseases in 1995.